- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2015–2022 · research · R01
Stress response networks in HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K01
Improving surgical decision-making in young women with breast cancer
Shoshana M Rosenberg · Dana-Farber Cancer Institute · funded by Agency for Healthcare Research and Quality
2015–2020 · research · R01
Targeting the p110beta isoform of PI3 kinase in prostate cancer
Massimo Loda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2028 · research · R35
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Targeting the p110beta isoform of PI3 kinase in prostate cancer
Massimo Loda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors
Nathanael Schiander Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors
Nathanael Schiander Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · cooperative agreement · U01
Genetics of Prostate Cancer in Africa
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers
Peter S Hammerman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Validating the eCyPA/CD147 signaling complex for myeloma therapy
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2025 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Stress response networks in HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2025 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2028 · research · R35
Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer
Loren David Walensky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Precision Medicine For Pediatric Low-Grade Gliomas
Daphne A. Haas-Kogan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
How do genome alterations cause human lung cancer?
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · cooperative agreement · U01
Genetics of Prostate Cancer in Africa
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer
Loren David Walensky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · award
Disparities in Breast Cancer Knowledge and Treatment Adherence
Rachel Freedman · Dana-Farber Cancer Institute · funded by American Cancer Society
2015–2022 · research · R35
How do genome alterations cause human lung cancer?
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Defining the epigenetic landscape in human prostate cancer
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · career development · K08
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Targeting the p110beta isoform of PI3 kinase in prostate cancer
Massimo Loda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · grant · BCRP
Randomized Trial of Asprin as Adjuvant Therapy for Node-Positive Breast Cancer
Wendy Chen · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2015–2022 · research · R35
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
Shuji Ogino · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Targeting the p110beta isoform of PI3 kinase in prostate cancer
Massimo Loda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Genetic evolution of glioblastomas during radiation and temozolomide therapy
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Defining the epigenetic landscape in human prostate cancer
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
Targeting intratumor heterogeneity in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Targeting the p110beta isoform of PI3 kinase in prostate cancer
Massimo Loda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Genetic evolution of glioblastomas during radiation and temozolomide therapy
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · award
Development of Novel Myeloma Therapies
Kenneth Anderson · Dana-Farber Cancer Institute · funded by American Cancer Society
2015–2022 · research · R35
Targeting intratumor heterogeneity in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2026 · research · R01
Evolution of gliomas during treatment and resistance
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · cooperative agreement · U01
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
Stephen J Elledge · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U01
Genetics of Prostate Cancer in Africa
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Defining the epigenetic landscape in human prostate cancer
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K01
Improving surgical decision-making in young women with breast cancer
Shoshana M Rosenberg · Dana-Farber Cancer Institute · funded by Agency for Healthcare Research and Quality
